<\/p>\n
Freenome (FRNM) only started trading publicly via a Special Purpose Acquisition Company, or SPAC, deal a few weeks ago on July 21, 2026.<\/p>\n
While Freenome isn’t nearly as familiar to investors as large drugmakers that usually dominate healthcare headlines, that may change now that a major Wall Street firm has initiated coverage and assigned a particularly strong forecast.<\/p>\n
On August 17, 2026, Jefferies analyst Tycho Peterson started coverage of Freenome Inc. with a ‘Buy’ rating and a $17 price target, CNBC reported.<\/p>\n
Shares jumped sharply in response, raising an obvious question: Is there something real behind the move, or is this just excitement around a fresh listing? <\/p>\n
The answer comes down to what the company has already built, and what still has to go right from here.<\/p>\n
Why Jefferies put a Buy rating and a $17 target on Freenome stock<\/p>\n
Jefferies’ target sits well above where the stock traded before the call. <\/p>\n
Freenome closed at $11.56 the previous session, so the target implies a roughly 47% increase from that level, Investing.com reported.<\/p>\n
More Healthcare Stocks:<\/p>\n
Morgan Stanley uncovers major Bristol Myers stock signals<\/p>\n
Goldman Sachs says one number will move Eli Lilly stock<\/p>\n
BofA stays bullish on Gilead after a strong HIV signal<\/p>\n
Investors moved fast on the news, with the stock jumping more than 12% to close at $13.00.<\/p>\n
Peterson’s case centers on Freenome moving from a research company to a commercial stage company.<\/p>\n
He told clients Freenome is “uniquely positioned,” with a multi-year growth ramp still ahead of it, CNBC noted.<\/p>\n
What Freenome actually does<\/p>\n
Freenome develops blood-based tests that look for early signs of cancer. <\/p>\n
A patient gives a normal blood sample, and the company’s platform scans it for warning signals.<\/p>\n
This matters because many people skip standard cancer screening. <\/p>\n
A colonoscopy takes preparation and time, and a stool-based test puts some patients off. A simple blood test removes those concerns.<\/p>\n
The company’s lead product is a colorectal cancer test called SimpleScreen. <\/p>\n
Freenome expects it to compete with established options like Cologuard from Exact Sciences (EXAS) and Shield from Guardant Health (GH), Investing.com reported.<\/p>\n
That is the core of the near-term business. The longer-term plan reaches much further.<\/p>\n
Freenome’s screening tests use a standard blood draw to look for early signs of cancer.<\/p>\n
SOPA Images \/ Getty Images<\/p>\n
The Abbott, Roche partnerships behind the bullish call<\/p>\n
Freenome is not trying to sell its colorectal test alone. It relies on two outside partners to reach patients and doctors.<\/p>\n
Abbott Laboratories (ABT) handles U.S. commercialization for the colorectal cancer test. <\/p>\n
Under the deal, Freenome received a $100 million milestone payment when the test won FDA clearance, according to MedTechDive. <\/p>\n
Abbott provides a large sales force and deep relationships across hospitals and clinics, something a young company cannot build overnight.<\/p>\n
Roche Holding (ROP) covers international markets and has exclusive rights outside the U.S. to develop “kitted” versions of Freenome’s tests. <\/p>\n
These packages combine the software and lab materials together, so smaller regional labs can run them without needing a large, centralized processing facility, Freenome confirmed. <\/p>\n
Roche is also a major investor in Freenome, having led a $254 million funding round in 2024.<\/p>\n
These deals shape the whole call. Jefferies pointed to royalties, milestone payments, and new cancer tests down the road as the ways value can flow to shareholders over time.<\/p>\n
From lung cancer to ten more tests: The expansion plan<\/p>\n
Colorectal cancer is the starting point, not the finish line. <\/p>\n
Freenome plans to widen its platform into other cancers, where the patient pools are far larger.<\/p>\n
Lung cancer is next in line. <\/p>\n
The FDA granted Breakthrough Device Designation to Freenome’s SimpleScreen Lung test in August 2026, according to the company’s press release.<\/p>\n
Related: UnitedHealth CFO sends stark warning after earnings<\/p>\n
The status is meant to speed the review of promising devices.<\/p>\n
The company aims to cover more than ten types of cancer over time, Investing.com reported. <\/p>\n
That is the source of the long-term optimism, since each new test adds a fresh potential revenue stream.<\/p>\n
None of that is guaranteed. Every new test still needs clinical data and regulatory clearance before it can be sold.<\/p>\n
The timeline Freenome investors should track<\/p>\n
Freenome moved from a private company to a public one in a matter of weeks, and its calendar is packed. <\/p>\n
Here are the dates that matter most.<\/p>\n
Key Freenome milestones and what they mean<\/p>\n
July 20, 2026: Freenome closed its merger with Perceptive Capital Solutions Corp., raising more than $300 million in gross proceeds through a private placement, according to the company’s press release.<\/p>\n
July 21, 2026: Shares began trading on the Nasdaq under the ticker FRNM.<\/p>\n
July 27, 2026: The FDA approved the Freenome and Abbott SimpleScreen colorectal cancer blood test.<\/p>\n
August 12, 2026: The FDA granted Breakthrough Device status to the lung cancer test.<\/p>\n
Fall 2026: Freenome and Abbott plan the broad U.S. launch of the colorectal test.<\/p>\n
Late 2027 or 2028: A U.S. Preventive Services Task Force review is expected.<\/p>\n
That last date is very important. <\/p>\n
If Freenome’s test gets included in the national screening guidelines, most insurance plans will start covering it. <\/p>\n
Wider coverage means more people can get the test, and that means more sales for Freenome.<\/p>\n
What still has to happen before the stock reaches $17<\/p>\n
Jefferies’ $17 target is not automatic. Three things need to go right first.<\/p>\n
The fall launch needs to go smoothly<\/p>\n
Freenome and Abbott plan to roll out the colorectal test widely this fall. <\/p>\n
If doctors and patients are slow to adopt it, revenue will be delayed, and the company will burn through cash faster.<\/p>\n
Freenome needs a win from federal health regulators <\/p>\n
The U.S. Preventive Services Task Force reviews cancer screening tests and decides which ones it recommends. <\/p>\n
Freenome already earned a spot in the American Cancer Society’s guidelines, Investing.com reported. But a recommendation from the federal task force is the bigger prize. <\/p>\n
That kind of endorsement is usually what convinces insurance companies to cover a test widely, which means more people can get it without paying out of pocket.<\/p>\n
The lung cancer test needs to keep clearing FDA hurdles<\/p>\n
Lung cancer screening would open up a much bigger group of patients than colorectal cancer alone. <\/p>\n
But the test is still working its way through development and regulatory review, so this part is not proven yet.<\/p>\n
The risks that could keep Freenome stock from getting there<\/p>\n
Freenome is small and still new to the public markets. That comes with real financial risk, so investors should size any position carefully.<\/p>\n
Here’s the current financial snapshot:<\/p>\n
Revenue: About $34 million over the last twelve months.<\/p>\n
Profit: None yet. The company is still unprofitable.<\/p>\n
Why: It’s spending heavily to launch its test commercially this fall.<\/p>\n
Market value: Around $1.3 billion.<\/p>\n
Early-stage biotechs like this one burn through cash quickly. If the fall launch is slow to catch on, two things could happen.<\/p>\n
Freenome might need to sell more stock to raise money. That would reduce the value of shares that current investors already own.<\/p>\n
If insurers are slow to cover the test, the company’s cash could run low faster than expected.<\/p>\n
Freenome also isn’t alone in this space. Exact Sciences and Guardant Health already sell their own colorectal screening tests. <\/p>\n
Both have longer relationships with doctors and insurers, which gives them a head start.<\/p>\n
What this means for investors<\/p>\n
Freenome is a high-risk, high-reward stock. That is the simplest way to describe it.<\/p>\n
The bull case is strong. Freenome has a broad testing platform and two experienced partners in Abbott and Roche.<\/p>\n
The risk is also just as real. The company has never proven it can sell a test at scale.<\/p>\n
The practical advice for most readers is to wait and watch before you act.<\/p>\n
The fall launch will tell you a lot. So will the next earnings report. <\/p>\n
Both will show whether doctors and patients are actually using the colorectal test, not just whether Wall Street likes the story.<\/p>\n
Remember that one analyst’s price target is not a guarantee. <\/p>\n
Tycho Peterson at Jefferies sees a path to $17 a share. That path still depends on execution that has not happened yet.<\/p>\n
If you are considering the stock, here are two steps to consider:<\/p>\n
Wait for sales data. Wait for the fall launch numbers before you buy.<\/p>\n
Keep any position small. Early-stage biotech stocks can swing sharply on a single earnings report, so size your investment so a bad quarter would not hurt you badly.<\/p>\n
Freenome has done the early work. It built the technology, lined up its partners, and won FDA approval.<\/p>\n
The next step is the hardest one. It has to prove people will actually use the test.<\/p>\n
Related: Jim Cramer crowns one surging sector the hottest in the market<\/p>\n
#Jefferies #sets #strong #price #target #upstart #cancer #stock<\/p>\n","protected":false},"excerpt":{"rendered":"
Freenome (FRNM) only started trading publicly via a Special Purpose Acquisition Company, or SPAC, deal…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[989,6095,100,480,91,573,336,19716],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14031"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14031"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14031\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}